Parallel Advisors, LLC Atreca, Inc. Transaction History

Parallel Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 20, 2024	BUY	$0.91 - $1.82 $7,383 - $14,767	8,114 New	8,114 $9,000
Q3 2022 Nov 10, 2022	SELL	$1.59 - $2.74 $1,014 - $1,748	-638 Reduced 7.29%	8,114 $13,000
Q1 2022 Apr 28, 2022	BUY	$1.61 - $5.2 $1,027 - $3,317	638 Added 7.86%	8,752 $28,000
Q4 2021 Jan 20, 2022	SELL	$2.87 - $6.29 $396 - $868	-138 Reduced 1.67%	8,114 $25,000
Q3 2021 Nov 02, 2021	BUY	$4.91 - $9.07 $677 - $1,251	138 Added 1.7%	8,252 $51,000
Q2 2020 Jul 16, 2020	BUY	$12.52 - $23.45 $101,211 - $189,569	8,084 Added 26946.67%	8,114 $172,000
Q3 2019 Nov 01, 2019	BUY	$10.42 - $22.04 $312 - $661	30 New	30 $0

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.